MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

523.47 1.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

511.24

Max

524.21

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+35.62% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 12B
Vorige openingsprijs	522.44
Vorige sluitingsprijs	523.47

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 apr 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Marktinformatie

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Marktinformatie

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Belangrijke Nieuwsgebeurtenissen

How Digital Currencies Have Helped Iran -- WSJ

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

35.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 35.62%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.